Demographics and Clinical Characteristics of Study Patients
| Sex | Age (y) | NET type | Tracer | Peptide (μg) | Ki-67 index | Previous surgery | History and previous therapy | Metastases | Ongoing therapy |
| F | 67 | pNET/NEC (glucagonoma) | TOC/TATE | 23/23 | 3% | — | SSA, streptozotocin-fluorouracil, PRRT, transformation to NEC and carboplatine-etopside | Liver | — |
| F | 63 | SI NET | TOC/TATE | 17/29 | 1% | Primary tumor | Liver trpl 1999 because of cyst disease | Liver, mesenteric lgl | — |
| M | 67 | SI NET | TOC/TATE | 18/30 | 1% | Primary tumor | — | Liver, mesenteric lgl | SSA |
| M | 50 | SI NET | TOC/TATE | 20/33 | 18% | Primary tumor mesenteric lgll | — | Liver, mesenteric lgl, retroperitoneal lgll | SSA |
| M | 64 | pNEC | TOC/TATE | 26/25 | 30% | — | Avastin, temozolomide | Liver | — |
| F | 73 | pNET | TOC/TATE | 22/22 | 3% | — | Streptozotocin-fluorouracil | Liver, abdominal lgll | SSA |
| M | 57 | SI NET | TOC | 25 | 3% | — | SSA | Abdominal lgll, mesenteric lgl | SSA |
| M | 53 | pNET (malignant insulinoma) | TOC | 18 | 3% | Primary tumor | Streptozotocin-fluorouracil, Sirtex | Liver, mesenteric lgl | Everolimus |
| F | 72 | pNET (MEN-1, gastrin-producing) | TOC | 15 | No biopsy | — | — | Retroperitoneal lgll | — |
| M | 51 | pNET | TOC | 22 | 3% | Primary tumor | — | Retroperitoneal lgll | — |
| M | 74 | SI NET | TOC | 23 | 1% | — | — | Mesenteric lgll | — |
| F | 67 | pNET | TOC | 25 | 2% | — | Streptozotocin-fluorouracil | Liver | — |
| M | 50 | SI NET | TOC | 47 | 4% | — | — | Liver, mesenteric lgl, peritoneal carcinomatosis | SSA |
| F* | 52 | SI NET | TOC | 25 | 5% | — | — | Liver, mesenteric thoracic neck lgll, bone, breast, ovary | SSA |
| F | 69 | SI NET | TOC | 27 | 9% | — | — | Liver, bone | SSA |
| F | 47 | SI NET | TOC | 41 | 9% | — | — | Liver, mesenteric lgl, abdominal and retroperitoneal lgll | SSA |
| M | 72 | Rectal NET | TATE | 13 | 30% | — | — | Liver, pararectal lgll | — |
| F | 69 | SI NET | TATE | 22 | 12% | — | — | Liver, peritoneal carcinomatosis | SSA |
| M | 67 | pNET | TATE | 8 | 17% | — | — | Liver, abdominal lgll, bone | SSA |
| M | 75 | Rectal NET | TATE | 14 | 10% | — | — | Liver, abdominal lgll, peritoneal carcinomatosis | — |
| F* | 53 | SI NET | TATE | 16 | 5% | Primary tumor | — | Liver, abdominal lgll, bone, breast, lung | SSA |
| F | 58 | Duodenal NET (gastrinoma) | TATE | 22 | 3% | Primary tumor liver resection, RF | — | Liver | SSA |
| F | 75 | Atypical lung NET | TATE | 39 | 6% | SSA |
↵* Same patient.
pNET = pancreatic NET; NEC = neuroendocrine carcinoma; TOC = 68Ga-DOTATOC; TATE = 68Ga-DOTATATE; SSA = long acting somatostatin analog; PRRT = peptide receptor radionuclide therapy; SI = small intestine; trpl = transplantation; lgl = single lymph node; lgll = multiple lymph nodes; Sirtex = transarterial liver embolization with 90Y-spheres; MEN-1 = multiple endocrine neoplasia type 1; RF = radiofrequency ablation.